ANN ARBOR, Michigan — Adeona Pharmaceuticals has enrolled half of the patients it hopes to sign up for trials of its multiple sclerosis drug Trimesta.
The company is in the midst of what it calls Phase “2/3” trials of Trimesta and has enrolled 75 of a planned 150 patients, according to a statement from the company. The company is enrolling women 18 to 50 years old who are suffering from so-called “relapsing-remitting” multiple sclerosis, a chronic disease that attacks the central nervous system. Relapsing-remitting refers to MS patients who experience clearly defined attacks of worsening neurologic functions that are followed by recovery periods in which the disease doesn’t progress, according to the National Multiple Sclerosis Society.
Adeona has received nearly $6 million for the clinical trials from the National Multiple Sclerosis Society and the National Institutes of Health. The company has completed a Phase 1 trial of the drug that showed Trimesta decreased the volume of myelin lesions, which occur when a MS patient’s immune system attacks the fatty substance that surrounds and protects nerve fibers in the central nervous system. Those lesions then cause scar tissue, or sclerosis, to form, giving the disease its name.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Earlier this month, Adeona hired a new chief executive, James Kuo, who has served on the company’s board since 2007. The company’s stock has surged in the last week, jumping 25 percent and breaking the $1 barrier. Adeona, which is traded on the American Stock Exchange, went public in 2006.
